DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20175089

Treatment outcomes in malignant ovarian germ cell tumors

Ram Kumar B.

Abstract


Background: Malignant ovarian germ cell tumours are rare group of ovarian neoplasms derived from primordial germ cells of the ovary. Objective of present study was to evaluate the outcome of treatment in malignant germ cell tumours.

Methods: 21 Patients of malignant ovarian germ cell tumours registered at Department of Medical Oncology, Institute of Obstetrics and Gynaecology, Chennai for the period from January 2012 to December 2015 were retrospectively analyzed for treatment outcomes.

Results: The median age at presentation was 21 years with age range between 14 and 40 years. 9patients (43%) presented with mixed germ cell tumour, 6 patients (29%) with dysgerminoma, 3 patients (14%) with yolk sac tumour and 3 patients (14%)with mature cystic teratoma. 13 patients (62%) presented with Stage I disease, 5 patients (24%) with Stage III and 3 patients (14%) with Stage II. Fertility sparing surgery was done in 15 patients (71%), and 4 patients (19%) who completed family had TAH with BSO done. Adjuvant Chemotherapy was given for 16 patients (76%) and as Neoadjuvant in 2patients (10%) who had biopsy alone performed. 4patients (19%) developed recurrence and was taken for salvage PVI chemotherapy.

Conclusions: Malignant ovarian germ cell tumours are relatively uncommon neoplasms characterized by high chemo sensitivity. This study confirms that malignant ovarian germ cell tumours have excellent prognosis and the effectiveness of BEP chemotherapy regimen. Fertility sparing surgery is feasible in most cases. Advanced Stage configured as an important risk factor for survival. The chemotherapy regimen was associated with significant but manageable toxicity.


Keywords


BEP Chemotherapy, Malignant ovarian germ cell tumour, Surgical treatment, Salvage Chemotherapy

Full Text:

PDF

References


Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994;12(4):701-6.

Tewari K, Cappuccini F, Disaia PJ, Berman ML, Manetta A, Kohler MF. Malignant germ cell tumors of the ovary. Obstet Gynecol. 2000 ;95(1):128-33

Gershenson DM, Update on malignant ovarian germ cell tumours, Cancer. 1993:71.1581-90.

Williams SD. Treatment of germ cell tumours of the ovary. Seminars in oncol.1991;18:292-6.

Bajorin DF, Sarosely MF, Pfister DG. Randomized trial of Etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumours, a multi institutional study. J Clin Oncol. 1993;11:598-606.

Pectasides D, Pectasides E, Kassanos D. Germ cell tumours of the ovary. Cancer Treat Rev. 2008;34:427.

Gershenson DM. Management of ovarian germ cell tumours. J Clin Oncol. 2007;25:2938-43.

Colombo N, Peiretti M, Castiglione M. Non epithelial ovarian cancer, ESMO clinical recommendation for diagnosis, treatment and followup. Annal Oncol. 2009;4:24-26.

Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, et al. Treatment of malignant germ cell tumours of ovary with bleomycin, etoposide and cisplatin. J Clin Oncol. 1990,8:715-20.

Williams SD, Blessing JA, Hatch KD, Homesley HD. Chemotherapy of advanced Dysgerminoma with cisplatin, etopoide and bleomycin, a trial of Gynaecologic Oncology Group. J Clin Oncol. 1991 Nov;9(11):1950-5.

Cushing B, Giller R, Ablin A, Cohen L, Cullen J, Hawkins E et al. Surgical treatment alone is effective for ovarian immature teratoma in children and adolescents, a report of pediatric oncology group and the children’s cancer group. Am J Obstet Gynecol. 1999;181:353-8.

Gershenson DM. Management of early ovarian cancer- germ cell and sex cord stromal tumours, Gynecol Oncol. 1994;55:562-7.

Morris HJ, Zirkin HJ, Benson WL. Germ cell tumours of ovary, a clinical and pathological study of 58 cases. Cancer. 1986;68(5)624-9.

Quirk JT, Natarajan N, Mettlin CJ. Age specific ovarian cancer incidence rate patterns in United States, Gynaecol Oncol. 2005;99:248-250.

Dimopoulos MA, Papadopoulou M, Andecapoulou E, Papadimitriou C, Pavlidis N, Aravantinos G, et al. Favourable outcome of Ovarian germ cell malignancies treated with cisplatin or carboplatin based chemotherapy. Gynecol Oncol. 1998;70:70-74.

Billimire D, Vinocur C, Rescorla F, Cushing B, Schlatter M, Davis M, et al. Outcome and staging evaluation in malignant germ cell tumours of ovary in children and adolescents: an Intergroup study. J Pediatric Surg. 2004;49:424-9.

Talukdar S, Kumar S, Bhatla N, Mathur S, Thulkar S, Kumar L. Neoadjuvant chemotherapy in treatment of advanced malignant germ cell tumours of ovary. Gynecol Oncol. 2014;132:28-32.

Mangili G, Sigismondi C, Gadducci A, Cormio G, Scollo P, Tateo S et al. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. Int J Gynecol Cancer. 2011 Nov 1;21(8):1414-21.

Williams SD, Brich R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated Germ cell tumours with Chemotherapy. N Eng J Med. 1987;316:1435-40.

Sklar CA, Matens AC, Mitby P, Whitton J, Stovall M, Kasper C et al. Premature menopause in survivors of childhood cancers, a report from childhood cancer survivor study. J National Cancer Institute. 2006,98:890-896.

Brenner M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol. 1999:17;2670-7.